Evaluating Epistem as a CRO Partner for Your Drug Programme

Epistem is a preclinical and clinical research services provider based in the UK that works across oncology, inflammatory disease, gastrointestinal disease (including GI toxicity), dermatology and biodefence, and it also runs GCLP-accredited laboratories supporting clinical trials. It is a plausible fit if your programme needs in vitro or in vivo disease models, organoids, or histology, immunohistochemistry, image analysis, gene expression and DNA genotyping work, and if you want protocols tailored to your study rather than a fixed catalogue. It is a weaker fit if you need a full-service CRO covering clinical operations, regulatory filing or manufacturing, since the site describes laboratory and analytical services rather than those functions. The practical way to decide is to map your therapeutic area and required readouts to the listed models and platforms, confirm accreditation and technique fit, then open a scoping conversation about your research goals.

Step 1: Match your therapeutic area to the research models

The site lists research models by disease area. Use this as a first filter before any technical discussion.

If your area is not on this list, that is not an automatic no — the site emphasises custom protocols — but treat it as a question to raise rather than an assumption.

Step 2: Check accreditation and platform fit

Two things matter here: whether the lab accreditation matches the stage of your study, and whether the specific technique you need is offered.

Accreditation. The site states its laboratories are GCLP-accredited and support clinical trials. GCLP (Good Clinical Laboratory Practice) is the relevant standard when your samples come from trial participants and the data may feed a regulatory submission. If your work is purely discovery-stage, this is less critical; if you are generating biomarker data from patients, ask directly which assays sit under the accredited scope, because accreditation usually applies to defined tests rather than the whole laboratory.

Platforms. The listed analytical platforms are multiplexed cytokine profiling, laser capture microdissection, flow cytometry and imaging. The listed services are RNAscope, high-throughput PCR, next-generation sequencing, histology and immunohistochemistry, the plucked hair biomarker platform, disease and pathway panels, bioinformatics, qPCR and microarray analysis, and gene expression analysis.

Build a short list of the readouts your programme actually needs and check each against this list. For example, if your endpoint is spatial gene expression in fixed tumour tissue, RNAscope plus imaging plus laser capture microdissection is a coherent combination to ask about in one conversation. If your endpoint is a circulating protein signature, multiplexed cytokine profiling is the relevant platform. Asking about techniques that are not listed is reasonable, but expect to hear whether they are in scope or handled through a partner.

Step 3: Test the custom-protocol and personalised-service claim

The site is explicit that the team delivers custom protocols and personalised services tailored to client needs, and that it has worked with more than 200 pharmaceutical and biotechnology companies. A client testimonial on the homepage praises professionalism and on-study and post-study support, including accommodation of unusual requests.

Treat these as claims to verify with your own study, not as guarantees. A useful test is to describe one concrete, slightly non-standard requirement — a bespoke dosing schedule, an unusual tissue collection window, a non-routine endpoint — and observe whether the response is a specific proposed design or a generic brochure reply. The former is evidence of the tailoring the site describes; the latter suggests you will be fitted to an existing protocol.

Step 4: Use the contact route to scope your study

The site's stated next step is to contact the team to discuss research goals and how they can help you achieve them. There is no published price list or self-service booking on the page, so budgeting and timelines have to come from that conversation.

Prepare a short brief before you make contact:

• Therapeutic area and indication, matched to the model list above.
• Stage: discovery, preclinical or clinical-trial sample analysis — this determines whether GCLP scope matters.
• Required readouts, named against the services and platforms list.
• Sample or animal numbers and your timeline.
• Any non-standard element, so you can test the custom-protocol claim.
• Questions on data handover: raw data, analysis outputs and bioinformatics support.

Ask in the same exchange about accreditation scope for your specific assays, expected turnaround, and how custom work is priced and scoped. Those answers, more than the homepage copy, will tell you whether Epistem fits your programme.

When Epistem is likely the right partner

• Your work sits in oncology, inflammation, GI disease or dermatology, or needs organoid or immune cell models.
• You need histology, IHC, image analysis, gene expression, genotyping or the listed molecular platforms, either standalone or alongside model work.
• You have clinical-trial samples requiring GCLP-accredited laboratory analysis.
• Your study has non-standard elements and you want a provider that builds protocols around them.

When to look elsewhere

• You need clinical trial operations, regulatory strategy or manufacturing, which the site does not describe.
• Your therapeutic area falls well outside the listed models and you cannot confirm coverage.
• You need published, self-service pricing before any conversation — nothing on the page supports that expectation.
• You need a single vendor to own the entire programme end to end rather than specialist laboratory and model services.